Volitionrx (VNRX) Convertible Debt (2025)

Volitionrx (VNRX) posted Convertible Debt of $1.4 million for Q4 2025, down 36.32% on a QoQ basis from $2.3 million in Q3 2025.

Volitionrx (VNRX) Convertible Debt (2025) Analysis & Trends

Volitionrx's Convertible Debt history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2025.

Quarterly Convertible Debt changed N/A year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, changed N/A from the prior year.
Convertible Debt was $1.4 million for Q4 2025 at Volitionrx, down from $2.3 million in the prior quarter.
Across five years, Convertible Debt topped out at $2.9 million in Q2 2025 and bottomed at $1.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Volitionrx	109,643.10	-2.35 Mn	-

Download Data